Skip to content
value.today

Dipexium Pharmaceuticals, LLC

🇺🇸 White Plains, New York, USAPharmaceuticalsFounded 2010
Total raised
$65 M
6 rounds on record
Latest round
$18 M
Nov 2020
First round on record
Jul 2010
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Dipexium Pharmaceuticals, LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2020$18 MNo. 6$10 to $50 million

Dipexium Pharmaceuticals, LLC: Raise no. 6, Nov 2020

Investors in this round

25 investors had bought by the notice of Nov 30, 2020: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$18 M of $18 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,020,325
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael J. Valentino · Executive Officer, Director
  • Natasha Giordano · Executive Officer, Director
  • Rita O'Connor · Executive Officer
  • Anthony J. Bartsh · Director
  • Gary J. Balkema · Director
  • John W. Hadden II · Director
  • Kirk J. Calhoun · Director
  • Robert J. Casale · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Raymond James & Associates, Inc. (CRD 705) · Saint Petersburg, FloridaSold in FL, GA, IL, NJ, NY, OH, TX, VA, VT

Signed by Rita O'Connor, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 30, 2020. Read the notice at the SEC.

equity, optionsSEC
May 2020$8 MNo. 5$2 to $10 million

Dipexium Pharmaceuticals, LLC: Raise no. 5, May 2020

Investors in this round

3 investors had bought by the notice of May 29, 2020: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$120,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael J. Valentino · Executive Officer, Director
  • Natasha Giordano · Executive Officer, Director
  • Rita O'Connor · Executive Officer
  • Anthony J. Bartsh · Director
  • Gary J. Balkema · Director
  • John W. Hadden II · Director
  • Kirk J. Calhoun · Director
  • Robert J. Casale · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Raymond James & Associates, Inc. (CRD 705) · Saint Petersburg, FloridaSold in NY

Signed by Rita O'Connor, Chief Financial Officer. Source: SEC Form D, newest notice filed May 29, 2020. Read the notice at the SEC.

equity, optionsSEC
Feb 2019$15 MNo. 4$10 to $50 million

Dipexium Pharmaceuticals, LLC: Raise no. 4, Feb 2019

Investors in this round

2 investors had bought by the notice of Mar 4, 2019: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,050,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Efthymios Deliargyris · Executive Officer
  • Michael J. Valentino · Executive Officer, Director
  • Natasha Giordano · Executive Officer, Director
  • Rita O'Connor · Executive Officer
  • Gary J. Balkema · Director
  • John W. Hadden II · Director
  • Kirk J. Calhoun · Director
  • Robert J. Casale · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • JMP Securities LLC (CRD 22208) · New York, New YorkSold in CA

Signed by Rita O'Connor, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 4, 2019. Read the notice at the SEC.

equity, optionsSEC
Jun 2017$18 MNo. 3$10 to $50 million

Dipexium Pharmaceuticals, LLC: Raise no. 3, Jun 2017

Investors in this round

37 investors had bought by the notice of Jun 28, 2017: 37 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$18 M of $18 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$1,191,512
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David J. Jorden · Executive Officer
  • Gary J. Mossman · Executive Officer
  • Michael J. Valentino · Executive Officer, Director
  • Natasha J. Giordano · Executive Officer, Director
  • David J. Luci · Director
  • Gary J. Balkema · Director
  • John J. Hadden · Director
  • Kirk J. Calhoun · Director
  • Robert J. Casale · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Raymond James & Associates, Inc. (CRD 705) · St. Petersberg, FloridaSold in CA, FL, NJ, NY, TX, VT
  • Janney Montgomery Scott LLC (CRD 463) · Philadelphia, PennsylvaniaSold in CA, FL, NJ, NY, TX, VT

Remarks in the notice

  • On fees: “Sales commission reflects amount paid in connection with (i) this offering and (ii) a concurrent public offering of common stock, consisting of a $1,091,512 fee and expenses up to $100,000 (including legal fees up to $75,000).”
  • On the use of proceeds: “No proceeds are proposed to be used for payments to such persons other than ordinary salary expenses that may be paid out of working capital.”

Signed by David Jorden, Acting CFO. Source: SEC Form D, newest notice filed Jun 28, 2017. Read the notice at the SEC.

optionsSEC
Jul 2013$3 MNo. 2$2 to $10 million

Dipexium Pharmaceuticals, LLC: Raise no. 2, Jul 2013

Investors in this round

28 investors had bought by the notice of Jul 22, 2013: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $6 M offered; $3 M still to sell
Smallest investment taken
$25,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • David P. Luci · Executive Officer, Director, Promoter
  • Robert J. DeLuccia · Executive Officer, Director, Promoter
  • Christopher J. Coughlin · Director
  • Ellen J. Zaroff · Director
  • Jack J. Dean · Director
  • John J. Leone · Director
  • John J. Terrana · Director
  • Michael J. Duffy · Director
  • Steven J. Hurd · Director
  • William J. McSherry, Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David P. Luci, Managing Partner. Source: SEC Form D, newest notice filed Jul 22, 2013. Read the notice at the SEC.

equity, optionsSEC
Jul 2010$3 MNo. 1$2 to $10 million

Dipexium Pharmaceuticals, LLC: Raise no. 1, Jul 2010

Investors in this round

34 investors had bought by the notice of Nov 7, 2011: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • David P. Luci · Executive Officer, Director, Promoter
  • Robert J. DeLuccia · Executive Officer, Director, Promoter
  • Jack J. Dean · Director
  • John J. Terrana · Director
  • Milos J. Koterec · Director
  • Steven D. Hurd · Director
  • William J. McSherry, Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “Issuer may pay fees of 6% for any investor introduced by a placement agent.”

Signed by David P. Luci, Managing Partner. Source: SEC Form D and 1 amendment, newest notice filed Nov 7, 2011. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Dipexium Pharmaceuticals, LLC chose not to state its revenue in its newest notice of a funding round (Nov 2020).

    SEC Form D · Nov 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2020

That is all the official record says: Dipexium Pharmaceuticals, LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Dipexium Pharmaceuticals, LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 37 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Dipexium Pharmaceuticals, LLC
NameRoleNamed in
Michael J. ValentinoExecutive officerNov 2020
Natasha GiordanoExecutive officerNov 2020
Rita O'ConnorExecutive officerNov 2020
Efthymios DeliargyrisExecutive officerMar 2019
David J. JordenExecutive officerJun 2017
Gary J. MossmanExecutive officerJun 2017
Natasha J. GiordanoExecutive officerJun 2017
David P. LuciExecutive officerJul 2013
Robert J. DeLucciaExecutive officerJul 2013
Anthony J. BartshDirectorNov 2020
Gary J. BalkemaDirectorNov 2020
John W. Hadden IIDirectorNov 2020
Kirk J. CalhounDirectorNov 2020
Michael J. ValentinoDirectorNov 2020
Natasha GiordanoDirectorNov 2020
Robert J. CasaleDirectorNov 2020
David J. LuciDirectorJun 2017
John J. HaddenDirectorJun 2017
Natasha J. GiordanoDirectorJun 2017
Christopher J. CoughlinDirectorJul 2013
David P. LuciDirectorJul 2013
Ellen J. ZaroffDirectorJul 2013
Jack J. DeanDirectorJul 2013
John J. LeoneDirectorJul 2013
John J. TerranaDirectorJul 2013
Michael J. DuffyDirectorJul 2013
Robert J. DeLucciaDirectorJul 2013
Steven J. HurdDirectorJul 2013
William J. McSherry, Jr.DirectorJul 2013
Milos J. KoterecDirectorNov 2011
Steven D. HurdDirectorNov 2011
David P. LuciPromoterJul 2013
Robert J. DeLucciaPromoterJul 2013